- Home
- GANX
as 07-26-2024 4:00pm EST
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BETHESDA |
| Market Cap: | 26.2M | IPO Year: | 2021 |
| Target Price: | $8.25 | AVG Volume (30 days): | 301.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $5.33 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1009.1% | Revenue Growth (next year): | -41.67% |
Stock Insider Trading Activity of Gain Therapeutics Inc. (GANX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RICHMAN ERIC I | GANX | Director | Jul 1 '24 | Buy | $1.21 | 12,000 | $14,520.00 | 289,629 | SEC Form 4 |
| RICHMAN ERIC I | GANX | Director | Jul 1 '24 | Buy | $1.23 | 5,000 | $6,150.00 | 277,629 | SEC Form 4 |
| Riley Jeffrey Scott | GANX | Director | Mar 28 '24 | Buy | $3.86 | 30,000 | $115,770.00 | 30,000 | SEC Form 4 |
Latest Gain Therapeutics Inc. News
GANX Breaking Stock News: Dive into GANX Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
Zacks
18 days ago
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
MT Newswires
24 days ago
HC Wainwright Trims Price Target on Gain Therapeutics to $8 From $9, Maintains Buy Rating
GlobeNewswire
a month ago
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
MT Newswires
a month ago
Gain Therapeutics Names Gene Mack as Interim Chief Executive Officer
GlobeNewswire
a month ago
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
GlobeNewswire
a month ago
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
GlobeNewswire
a month ago
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Compare GANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GANX Gain Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.